The stock has a 36-month beta value of 1.51. Opinions on the stock are mixed, with 1 analysts rating it as a “buy”, 0 as “overweight”, 1 as “hold”, and 0 as “sell”.
The public float for CTXR is 20.27M, and at present, short sellers hold a 13.42% of that float. On February 12, 2026, the average trading volume of CTXR was 831.01K shares.
CTXR stock’s latest price update
Citius Pharmaceuticals Inc (NASDAQ: CTXR) has experienced a rise in its stock price by 10.82% compared to its previous closing price of $0.81. However, the company has seen a gain of 16.58% in its stock price over the last five trading days.
CTXR’s Market Performance
Citius Pharmaceuticals Inc (CTXR) has experienced a 16.58% rise in stock performance for the past week, with a 1.66% rise in the past month, and a -29.74% drop in the past quarter. The volatility ratio for the week is 13.42%, and the volatility levels for the past 30 days are at 8.02% for CTXR. The simple moving average for the last 20 days is 11.55% for CTXR’s stock, with a simple moving average of -22.40% for the last 200 days.
Analysts’ Opinion of CTXR
Many brokerage firms have already submitted their reports for CTXR stocks, with D. Boral Capital repeating the rating for CTXR by listing it as a “Buy”. The predicted price for CTXR in the upcoming period, according to D. Boral Capital is $9 based on the research report published on December 30, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see CTXR reach a price target of $4. The rating they have provided for CTXR stocks is “Buy” according to the report published on November 30th, 2021.
CTXR Trading at -3.73% from the 50-Day Moving Average
After a stumble in the market that brought CTXR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.72% of loss for the given period.
Volatility was left at 8.02%, however, over the last 30 days, the volatility rate increased by 13.42%.
Stock Fundamentals for CTXR
The total capital return value is set at -0.45%. Equity return is now at value -54.40%, with -30.21% for asset returns.
Based on Citius Pharmaceuticals Inc (CTXR), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -14.64. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -143.87.
Currently, EBITDA for the company is -$38.2 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.62.
Conclusion
To sum up, Citius Pharmaceuticals Inc (CTXR) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.